Tools   Select Another Resource Report Type

https://www.cincinnatichildrens.org/research/divisions/d/dhc/cores/integrative-morphology/confocal-imaging

Provides Cincinnati Children s Hospital Medical Center; Cincinnati; Ohio resources in confocal, wide-field, and spatial technique applications.

Proper citation: Cincinnati Children's Hospital Confocal Imaging Core Facility (RRID:SCR_022628) Copy   

•   Source: SciCrunch Registry

https://ncdiabetesresearch.org/acsmc

Core to leverage data, patient populations and investigators at each NCDRC institution, including accessing expertise and resources of regional Clinical and Translational Science Institute hubs (Duke, UNC, and Wake Forest). Research navigators in ACSMC provides input and navigation of clinical research resources available to diabetes investigators based on extensive experience in diabetes specific studies and methodology and deep knowledge of NCDRC resources available at each institution.

Proper citation: North Carolina Diabetes Research Center Advanced Clinical Study Methods Core Facility (RRID:SCR_022908) Copy   

•   Source: SciCrunch Registry

https://medschool.cuanschutz.edu/diabetes-research-center/diabetes-research-center/drc-cores/cell-and-tissue-analysis

Provides diabetes researchers at University of Colorado with access to microscopy and mass cytometry systems. Provides expertise and training to use equipment effectively for diabetes related tissues; expertise and validated diabetes related resources to prepare samples appropriately; guidance to design experiments; resources to analyze data; assistance with data interpretation.

Proper citation: University of Colorado Anschutz Medical Campus Diabetes Research Center Cell and Tissue Analysis Core Facility (RRID:SCR_022906) Copy   

•   Source: SciCrunch Registry

https://medschool.cuanschutz.edu/diabetes-research-center/diabetes-research-center/drc-cores/diabetes-modeling

Provides diabetes researchers with access to novel human stem cell-derived in vitro cell models for investigating cellular and molecular features of both Type 1 and Type 2 diabetes. Recent progress in stem cell, organoid culture, gene editing and directed differentiation technologies has afforded opportunities to develop pre-clinical human models.Provides expertise, infrastructure and access to novel human model systems and technologies to DRC investigators. Provides expertise, resources and training in stem cell technologies together with quality control testing, validation standardization and authentication all model platforms and reagents.

Proper citation: University of Colorado Anschutz Medical Campus Diabetes Research Center Disease Modeling Core Facility (RRID:SCR_022905) Copy   

•   Source: SciCrunch Registry

https://medschool.cuanschutz.edu/diabetes-research-center/diabetes-research-center/drc-cores/clinical-resources

Core leverages current clinical research facilities and equipment available at Barbara Davis Center for Childhood Diabetes, UC AMC Clinical Translational Research Center, University of Colorado Hospital, Denver Veteran Administration Medical Center and Children Hospital Colorado.Core integrates diabetes research across these institutions through communication and distribution of resources available, and creates shared sample and data biobanks and recruiting database of mothers, infants, children, adolescents and adults with diabetes, diabetes risk and controls.

Proper citation: University of Colorado Anschutz Medical Campus Diabetes Research Center Clinical Resource Core Facility (RRID:SCR_022903) Copy   

•   Source: SciCrunch Registry

https://www.atypicaldiabetesnetwork.org/

Portal dedicated to characterizing, discovering and defining rare and atypical forms of diabetes. Network of universities, hospitals and clinics across the United States dedicated to better understanding atypical diabetes. Team of academic institutions and scientists collaborates with physicians and healthcare groups to identify those with atypical diabetes and learn more about their health.

Proper citation: Rare and Atypical Diabetes Network (RRID:SCR_024732) Copy   

•   Source: SciCrunch Registry

https://www.signalingpathways.org/ominer/query.jsf

THIS RESOURCE IS NO LONGER IN SERVICE.Documented on February 25, 2022.Software tool as knowledge environment resource that accrues, develops, and communicates information that advances understanding of structure, function, and role in disease of nuclear receptors (NRs) and coregulators. It specifically seeks to elucidate roles played by NRs and coregulators in metabolism and development of metabolic disorders. Includes large validated data sets, access to reagents, new findings, library of annotated prior publications in field, and journal covering reviews and techniques.As of March 20, 2020, NURSA is succeeded by the Signaling Pathways Project (SPP).

Proper citation: Nuclear Receptor Signaling Atlas (RRID:SCR_003287) Copy   

•   Source: SciCrunch Registry

http://www.cristudy.org/Chronic-Kidney-Disease/Chronic-Renal-Insufficiency-Cohort-Study/

A prospective observational national cohort study poised to make fundamental insights into the epidemiology, management, and outcomes of chronic kidney disease (CKD) in adults with intended long-term follow up. The major goals of the CRIC Study are to answer two important questions: * Why does kidney disease get worse in some people, but not in others? * Why do persons with kidney disease commonly experience heart disease and stroke? The CRIC Scientific and Data Coordinating Center at Penn receives data and provides ongoing support for a number of Ancillary Studies approved by the CRIC Cohort utilizing both data collected about CRIC study participants as well as their biological samples. The CRIC Study has enrolled over 3900 men and women with CKD from 13 recruitment sites throughout the country. Following this group of individuals over the past 10 years has contributed to the knowledge of kidney disease, its treatment, and preventing its complications. The NIDDKwill be extending the study for an additional 5 years, through 2018. An extensive set of study data is collected from CRIC Study participants. With varying frequency, data are collected in the domains of medical history, physical measures, psychometrics and behaviors, biomarkers, genomics/metabolomics, as well as renal, cardiovascular and other outcomes. Measurements include creatinine clearance and iothalamate measured glomerular filtration rate. Cardiovascular measures include blood pressure, ECG, ABI, ECHO, and EBCT. Clinical CV outcomes include MI, ischemic heart disease-related death, acute coronary syndromes, congestive heart failure, cerebrovascular disease, peripheral vascular disease, and composite outcomes. The CRIC Study has delivered in excess of 150,000 bio-samples and a dataset characterizing all 3939 CRIC participants at the time of study entry to the NIDDKnational repository. The CRIC Study will also be delivering a dataset to NCBI''''s Database for Genotypes and Phenotypes.

Proper citation: Chronic Renal Insufficiency Cohort Study (RRID:SCR_009016) Copy   

•   Source: SciCrunch Registry

http://www.uchicagoddrcc.org/research-cores/tissue-engineering-and-cell-models-core

Core that provides services such as a repository for intestinal cell lines, Tissue Engineering Models, experimental materials, and supplies for digestive disease research.

Proper citation: University of Chicago Digestive Diseases Research Core Center Tissue Engineering and Cell Models Core (RRID:SCR_015604) Copy   

•   Source: SciCrunch Registry

https://joslinresearch.org/drc-cores/Flow-Cytometry-Core

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 27,2023. Core that provides cell sorting and flow cytometry services. Specific services include cell analysis, large object sorting,magnetic cell enrichment, and automatic cell counting.

Proper citation: Joslin Diabetes Center Flow Cytometry Core Facility (RRID:SCR_009878) Copy   

•   Source: SciCrunch Registry

https://joslinresearch.org/drc-cores/Animal-Physiology-Core

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 27,2023. Core that provides technically advanced physiological evaluation of metabolism in diabetes, obesity, and their associated complications in rodents for DRC investigators and outside users. It also provides training of investigators and trainees in several physiological procedures.

Proper citation: Joslin Diabetes Center Animal Physiology Core Facility (RRID:SCR_009876) Copy   

•   Source: SciCrunch Registry

https://joslinresearch.org/drc-cores/Advanced-Microscopy-Core

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 27,2023. Core that provides services for performing specific morphological procedures, providing training and access to equipment, maintaining the specialized microscopes, and giving advice and interpretation.

Proper citation: Joslin Diabetes Center Advanced Microscopy Core Facility (RRID:SCR_009875) Copy   

•   Source: SciCrunch Registry

https://joslinresearch.org/drc-cores/Advanced-Genomics-and-Genetics-Core

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 27,2023. Core that provides services for genetic and genomic analysis, including DNA extraction from blood, access to DNA collections from the Core?s repository, SNP genotyping, and support for gene expression studies based on both high-density oligonucleotide arrays and real-time quantitative PCR.

Proper citation: Joslin Diabetes Center Advanced Genomics and Genetics Core Facility (RRID:SCR_009873) Copy   

•   Source: SciCrunch Registry

http://www.med.upenn.edu/idom/drc/cores/ria.html

Core which offers high quality immunoassay services to basic, translational, and clinical investigators performing diabetes and related metabolic disease research. The core also provides consultation and training and education services.

Proper citation: Penn Diabetes Research Center Radioimmunoassay and Biomarkers Core Facility (RRID:SCR_010028) Copy   

•   Source: SciCrunch Registry

http://www.med.upenn.edu/gtp/vectorcore/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 30,2023. Core whose main aim is to provide vector technology for preclinical studies and other basic research applications. Its services include rovision of AAV, adenoviral and lentiviral based vectors, consultation and advice in the design of custom vectors and in vector serotype/pseudotype selection, and design, cloning and production of plasmid DNA for the production of custom vectors.

Proper citation: University of Pennsylvania Center for Molecular Therapy for Cystic Fibrosis Vector Core Facility (RRID:SCR_010038) Copy   

•   Source: SciCrunch Registry

https://labnodes.vanderbilt.edu/community/profile/id/2229

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 30,2023. Core facility that provides any Vanderbilt researcher with access to imaging equipment and expert technical support for microscopy and analysis of tissue and cellular physiology.

Proper citation: Vanderbilt Diabetes Research and Training Center Cell Imaging Shared Resource Core Facility (RRID:SCR_010165) Copy   

•   Source: SciCrunch Registry

https://labnodes.vanderbilt.edu/community/profile/id/2230

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 30,2023. Core facility that supports diabetes, endocrine, and metabolic research across a range of species. Its objective is to provide sensitive, reproducible, and inexpensive analyses of hormones, amino acids, and other relevant chemicals.

Proper citation: Vanderbilt Diabetes Research and Training Center Hormone Assay and Analytical Services Core Facility (RRID:SCR_010181) Copy   

•   Source: SciCrunch Registry

https://hddc.hms.harvard.edu/gnotobiotics-microbiology-and-metagenomics

Core facility that assists investigators evaluating host microbiota and its role in normal physiology and disease. It includes a number of resources for groups studying the role of the microbiota in human health and disease.

Proper citation: Harvard Digestive Diseases Center Biomedical CORE D: Gnotobiotic Mice, Microbiology and Metagenomics (RRID:SCR_012319) Copy   

•   Source: SciCrunch Registry

http://www.t1diabetes.nih.gov/T1D-PTP/

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 22, 2016. Investigator access is provided to the established facilities and expertise needed to extend, enhance and validate preclinical studies of promising new therapeutics in cases where additional preclinical testing is needed to validate potential therapies under disease-specific conditions and in multiple animal models before therapeutics can enter the Type 1 Diabetes Rapid Access to Intervention Development (T1D-RAID) development pipeline. The T1D-RAID program provides resources for pre-clinical development of drugs, natural products, and biologics that will be tested as new therapeutics in type 1 diabetes clinical trials. The T1D-RAID program is not currently accepting applications. The T1D-PTP program currently supports two contracts, which are separate from each other and from the T1D-RAID NCI contract resources, to assist in preclinical development of therapeutics for T1D: * Agents to be tested for Preclinical Efficacy in Prevention or Reversal of Type 1 Diabetes in Rodent Models. Type 1 Diabetes Preclinical Testing Program (T1D-PTP) (NOT-DK-09-006) * Needs for Preclinical Efficacy Testing of Promising Agents to Prevent or Reverse Diabetic Complications (NOT-DK-09-009) The T1D-RAID and T1D-PTP are programs intended to remove the most common barriers to progress in identification and development of new therapies for Type 1 Diabetes. The common goal of these programs is to support and provide for the preclinical work necessary to obtain proof of principle establishing that a new molecule or novel approach will be a viable candidate for expanded clinical evaluation.

Proper citation: Type 1 Diabetes Preclinical Testing Program (RRID:SCR_006861) Copy   

•   Source: SciCrunch Registry

http://diabetes.niddk.nih.gov/dm/pubs/control/index.aspx

Clinical study that showed that keeping blood glucose levels as close to normal as possible slows the onset and progression of eye, kidney, and nerve diseases caused by diabetes. EDIC is a follow-up study of people who participated in DCCT. The DCCT involved 1,441 volunteers, ages 13 to 39, with type 1 diabetes and 29 medical centers in the United States and Canada. Volunteers had to have had diabetes for at least 1 year but no longer than 15 years. They also were required to have no, or only early signs of, diabetic eye disease. The study compared the effects of standard control of blood glucose versus intensive control on the complications of diabetes. Intensive control meant keeping hemoglobin A1C levels as close as possible to the normal value of 6 percent or less. The A1C blood test reflects a person''''s average blood glucose over the last 2 to 3 months. Volunteers were randomly assigned to each treatment group. DCCT Study Findings * Intensive blood glucose control reduces risk of ** eye disease: 76% reduced risk ** kidney disease: 50% reduced risk ** nerve disease: 60% reduced risk When the DCCT ended, researchers continued to study more than 90 percent of participants. The follow-up study, called Epidemiology of Diabetes Interventions and Complications (EDIC), is assessing the incidence and predictors of cardiovascular disease events such as heart attack, stroke, or needed heart surgery, as well as diabetic complications related to the eye, kidney, and nerves. The EDIC study is also examining the impact of intensive control versus standard control on quality of life. Another objective is to look at the cost-effectiveness of intensive control. EDIC Study Findings * Intensive blood glucose control reduces risk of ** any cardiovascular disease event: 42% reduced risk ** nonfatal heart attack, stroke, or death from cardiovascular causes: 57% reduced risk

Proper citation: Diabetes Control and Complications Trial (RRID:SCR_006805) Copy   

•   Source: SciCrunch Registry